Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

85 results about "Intravenous IG" patented technology

Intravenous immune globulin (IVIG) is made of antibodies that have been extracted from blood donations from 3,000-10,000 healthy donors. IVIG is used to treat many autoimmune disorders, idiopathic diseases (disease of unknown cause), and infections.

Multifunctional self-bionic nano vaccine for treating breast cancer as well as preparation method and application of multifunctional self-bionic nano vaccine

The invention provides a multifunctional self-bionic nano vaccine for treating breast cancer. The multifunctional self-bionic nano vaccine comprises MnOx nano particles serving as inner cores and fusion cell membranes wrapping the surfaces of the inner cores of the MnOx nano particles, the fused cell membrane is obtained by fusing a remodeled 4T1 cell membrane and a remodeled DC cell membrane. According to the invention, the nano vaccine can play an immunotherapy role in treating breast cancer under the condition of subcutaneous injection. After subcutaneous peritumoral injection, the multifunctional autologous bionic nano vaccine can target tumor tissues to play an in-situ chemical power treatment role, chemotactic to drainage lymph nodes to realize efficient T cell immune response to play an immunotherapy role, and main organs of the whole body are less gathered, so that the vaccine is safe and reliable; the SPNE prepared in the prior art can cause a certain liver aggregation effect after intravenous injection, and great toxic and side effects are generated.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

Method for Treating Antibody-Mediated Rejection Post-Transplantation

Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).
Owner:CEDARS SINAI MEDICAL CENT

Targeted immunotolerance vaccine, preparation method therefor, and use thereof

PCT designated stageWO2025237213A1AntipyreticAnalgesicsTolerance inductionApoptosis
Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.
Owner:SUZHOU UNIV

Preparation method and application of genetically modified mesenchymal stem cell-derived exovesicles

The invention discloses a preparation method and application of genetically modified mesenchymal stem cell-derived exovesicles, and relates to the technical field of biological medicines. The method comprises the following steps: 1) establishing a three-dimensional suspension culture system for stably overexpressing PD-L1 and ICAM-1 gene mesenchymal stem cell strains; and 2) a preparation method of the mesenchymal stem cell source outer vesicles of the high-purity overexpression PD-L1 and ICAM-1 genes. After an immune thrombocytopenia mouse model is intravenously injected with the mesenchymal stem cell source outer vesicles of the overexpressed PD-L1 and ICAM-1 genes, the number of platelets can be remarkably increased, and subcutaneous purpura disappears. A research result shows that the mesenchymal stem cell-derived outer vesicles with high-purity overexpression of PD-L1 and ICAM-1 have a relatively good market application prospect.
Owner:XIAN CHAOYUE STEM CELL TECH CO LTD

Brain glioma animal model construction method based on AAV mediated immune microenvironment

The invention discloses a brain glioma animal model construction method based on an AAV mediated immune microenvironment. The method comprises the following steps: selecting an immunodeficient mouse at the right age; human CD34 + hematopoietic stem cells are injected for immune system reconstruction; human CD45 + immune cells in the peripheral blood PBMC are detected; the method comprises the following steps: selecting tumor tissues with high-expression brain glioma marker genes, carrying out rapid qPCR (quantitative polymerase chain reaction) or targeted RNA-seq immunohistochemical multiple verification, and screening consistent tumor tissues; the method comprises the following steps: physically dicing tumor tissues, treating the tumor tissues with pretreatment liquid, digesting the tumor tissues into single-cell suspension, and inoculating the single-cell suspension into a mouse cranium; an AAV vector carrying a specific immune regulation gene is injected into the tail vein of the mouse, and the brain glioma immune microenvironment is regulated; when it is observed that the tumor tissue grows stably and has immune cell infiltration characteristics, construction of the brain glioma animal model is completed. Compared with an existing model, the brain glioma model which is more stable, more scientific and closer to the human immune background is provided, and the brain glioma model is suitable for related immunotherapy drug screening and mechanism research.
Owner:NIKETHERAPEUTICS (HANGZHOU) CO LTD

Mesenchymal stem cell preparation as well as preparation method and application thereof

The invention relates to the technical field of stem cells, in particular to a mesenchymal stem cell preparation as well as a preparation method and application thereof. The mesenchymal stem cell preparation disclosed by the invention is obtained by mixing human umbilical cord mesenchymal stem cells and a human fibroblast growth factor FGF23. After the mesenchymal stem cell preparation is intravenously injected into an autoimmune hepatitis mouse model, the liver inflammation state and damage of the autoimmune hepatitis mouse can be remarkably improved, liver repair is promoted, and the main manifestation is that the contents of alanine transaminase (ALT), aspartate transaminase (AST) and inflammatory cytokines in serum are remarkably reduced, and the content of the inflammatory cytokines is remarkably reduced. The content of an anti-inflammatory factor (IL-10) for promoting inflammation fading is remarkably increased, the content of cytotoxic T cells (CTL, CD8 + CD3 +) is remarkably reduced, and the content of regulatory T cells (Treg, CD4 + CD25 +) is remarkably increased.
Owner:NANJING UNIV +1

Mouse PDX cell and construction method of humanized systemic lupus erythematosus mouse model

The invention provides a mouse PDX cell and a construction method of a humanized systemic lupus erythematosus (SLE) mouse model, and belongs to the technical field of animal model construction. The invention provides a mouse PDX cell L0407-6-P3 which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2024181. After the mouse PDX cell L0407-6-P3 is intravenously injected into an NSG mouse, the mouse disease is stable, the human SLE disease phenotype can be generated, the multi-system and multi-organ inflammatory response and injury of human SLE can be better simulated, the mouse PDX cell L0407-6-P3 can be used for constructing a humanized systemic lupus erythematosus mouse model, the blank of the current humanized SLE animal model is filled, and the mouse PDX cell L0407-6-P3 has better popularization and application values.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Replicant / STAV for disease treatment and methods of use

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.
Owner:BARBER GLEN N

In vivo nickase-based editing of the LPA gene for treatment of cardiovascular disease

Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the LPA gene. Treatment or prevention of cardiovascular disease through disruption of the production of apo(a) through genetic editing and the reduction of the blood lipoprotein(a) [Lp(a)] concentration is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and / or deletions (indel variants) and / or non-synonymous variants in the coding sequence of LPA. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.
Owner:VERVE THERAPEUTICS INC

Replicant / STAV for disease treatment and methods of use

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV / Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV / Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV / Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV / Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APCs.
Owner:BARBER GLEN

Anti-mast cell antibodies

The present invention relates to methods of depleting mast cells. The invention also relates to methods of treating a mast cell disease in a subject in need thereof. The methods involve the administration of an anti-mast cell antibody wherein the antibody is administered via a slow absorption delivery route, in particular wherein the antibody is administered subcutaneously. Administration of anti-mast cell antibodies via a slow absorption delivery route, for example subcutaneously or intradermally, can avoid the anaphylaxis seen when anti-mast cell antibodies are administered via alternative routes e.g. intravenously.
Owner:ARGENX BVBA(BE)

Cell membrane bionic drug-loaded carbon dot nano material as well as preparation method and application thereof

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.
Owner:DONGHUA UNIV

Safe and effective method of treating ulcerative colitis with Anti-il12 / il23 antibody

Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and / or subcutaneous administration of an anti-IL-12 / IL-23p40 antibody.
Owner:JANSSEN BIOTECH INC

Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

To provide a pharmaceutical formulation comprising trehalose for use in treating myopathies, neurodegenerative diseases, or tauopathies associated with abnormal protein aggregation.SOLUTION: A pharmaceutical formulation comprising a therapeutically effective amount of trehalose is provided, wherein the pharmaceutical formulation is for use in a method for treating a disease associated with abnormal protein aggregation and / or inclusion bodies formation in myocytes, neurons, or extracellular compartments, or for alleviating at least one symptom associated therewith in a human subject in need thereof, the method comprising intravenously administering to the subject a pharmaceutical formulation comprising 0.1% (w / v) to 50% (w / v) of trehalose. An injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose is also provided.SELECTED DRAWING: None
Owner:BIO BLAST PHARMA

Preparation method and application of tumor exosome loaded gamma delta T cell

The invention discloses a preparation method and application of tumor exosome loaded gamma delta T cells. The tumor exosome-loaded gamma delta T cells are researched to be used for treating lung cancer, after the gamma delta T cells and the tumor cell exosome-loaded gamma delta T cells are co-cultured with lung cancer tumor cells respectively, a large number of tumor cell exosome-loaded gamma delta T cells surround the tumor cells, the tumor cells are attacked, and the tumor cell exosome-loaded gamma delta T cells are used for treating lung cancer. And the gamma delta T cells do not attack surrounding tumor cells. The tumor cell exosome loaded gamma delta T cells are intravenously injected into multiple lung cancer patients, compared with the prior art, the proportion of CD3 + and CD4 + positive cells is remarkably increased after 4 cycles and 6 months after treatment, the proportion of CD8 + positive cells is remarkably reduced, the ratio of CD4 + / CD8 + is remarkably increased after 6 months, and the number of NK cells is remarkably increased after 4 cycles after treatment, so that the tumor cell exosome loaded gamma delta T cells can be used for treating the lung cancer patients. The tumor exosome loaded gamma delta T cell has a good anti-tumor effect.
Owner:YUNNAN JIAKANG BIOTECHNOLOGY CO LTD

Methods of making nk cells, nk cells, and uses thereof

PendingCN122128232ANervous disorderBlood/immune system cellsCD16Aβ oligomers
This invention discloses a method for preparing NK cells, the NK cells obtained thereby, and their applications. The method includes: sorting NK cells from peripheral blood of an allogeneic donor; culturing them in a serum-free medium containing CD3 monoclonal antibody, CD16 antibody, and IL-2, without the need for a feeder layer; preferably, IL-21 is added for amplification on days 3-5 of culture, and the cells are cultured for 20-40 days. This method yields non-genetically modified NK cells, among which CD56... bright The NK cells comprise >90% of the cell line and highly express a variety of activating and functional molecules. These NK cells effectively clear Aβ oligomers and senescent cells, and alleviate neuroinflammation. In treatment, intracranial injection achieves equivalent or better efficacy with only about 1 / 10th the dose administered intravenously, significantly clearing Aβ deposits in the brains of AD model mice and improving pathology.
Owner:SHANGHAI NK CELLTECH CO LTD

Stable pharmaceutical formulation

A stable pharmaceutical formulation according to the present invention comprises: (A) Ixekizumab; and (B) a histidine buffer. A stable pharmaceutical formulation according to the present invention comprises an antibody, has excellent long-term storage stability on the basis of having excellent stability especially under accelerated conditions and severe conditions, and can be administered intravenously or subcutaneously.
Owner:CELLTRION INC

Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Owner:HORIZON THERAPEUTICS USA INC

A preparation process of human immunoglobulin preparation for intravenous injection

The present invention provides a preparation process of a human immunoglobulin preparation for intravenous injection, which belongs to the field of protein production technology. The preparation process provided by the present invention comprises: dissolving the component II+III precipitate with a precipitation dissolving solution containing 0.8%-1.2% sodium dihydrogen phosphate and 0.66%-1.0% sodium citrate, adding low-temperature ethanol, adding a filter-aid mixed powder for filter pressing, wherein the weight ratio of diatomaceous earth, cellulose and silicon dioxide in the filter-aid mixed powder is 4-5:2-3:1-1.5. The human immunoglobulin preparation for intravenous injection prepared by the present invention has an anti-complement activity of only 5%-7%, has good thermal stability, and a purity of up to 99.3%-100%.
Owner:SHANDONG BAIYI PHARMA

Engineered Plant Virus-Based Nanoparticles and Intravenous Formulations Thereof for Autoimmune Therapy

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.
Owner:DIAMANTE SOCIETA BENEFIT SRL

New strategy for delivering cGAMP molecules

The invention belongs to the field of biological medicines, and particularly relates to a method for delivering a natural activator of an interferon stimulating factor gene (STING) and cyclic GMP-AMP (cGAMP) molecules into cells by utilizing silicon dioxide nanoparticles which are 200 nanometers in diameter, externally coated with solid silicon dioxide spines, modified with positive charges on the surfaces and 40-60 nanometers in spur length range. And a new strategy for activating the STING pathway to increase immunity is provided. Administration modes include but are not limited to intranasal administration, intramuscular injection, caudal vein injection and the like. The cGAMP molecule is an endogenous second messenger molecule, is formed by cyclizing two nucleotides, and has the potential of being applied to treatment of tumors, infectious diseases, autoimmune diseases and the like in the pharmaceutical aspect. Due to negative charges and hydrophilicity, cGAMP molecules cannot penetrate through cell membranes to exert pharmacological effects. According to the invention, the special silicon dioxide nanoparticles are utilized to help the cGAMP enter the cells to play a pharmacological role, so that the method has potential pharmaceutical application value, and a brand new strategy is provided for clinical application of cGAMP molecules.
Owner:HAINAN UNIV

Method for in-vivo detection of tumor cell killing effect of NK cells

The invention relates to the technical field of tumor cell killing, in particular to a method for in-vivo detection of the tumor cell killing effect of NK cells, and the method comprises the following steps: S1, taking killing of male C57BL / 6 mouse NK cells on Hela cells and other types of human-derived tumor cells under in-vivo conditions as a model, and taking the Hela cells as a contrast; s2, grouping the selected mice, and correspondingly performing intraperitoneal injection of isotype IgG, an anti-NK1.1 antibody and an anti-mouse NKG2D monoclonal antibody; s3, preparing a cell mixed solution of to-be-detected tumor cells and Hela cells; s4, injecting the cell mixed liquid into the body of the mouse in a caudal vein injection manner; s5, killing each group of mice, and taking lungs to prepare a single-cell suspension; s6, detecting the number of CFSE positive cells and the number of PKH26 positive cells in the mouse lung single-cell suspension by adopting a flow cytometer; and S7, calculating the survival rate of the tumor cells to be detected. The method well solves the problem that the killing effect of the NK cells on the human tumor cells is difficult to accurately and truly evaluate in the prior art.
Owner:ZHEJIANG MEDICAL COLLEGE

Epigenetic editing system

The invention belongs to the field of nucleic acid editing, and particularly relates to the technical field of regularly clustered interval short palindromic repeat (CRISPR). Specifically, Cas9 or smaller Cas-SF01 (a Cas12i3 variant) is utilized to reasonably design and construct a compact mRNA-delivered epigenetic suppressor in an engineering manner, and an optimized mRNA structure, lipid nanoparticle (LNP) delivery, OFF-E-V2 mRNA optimized by single intravenous injection and selected guide RNA (gRNA) targeting mouse PCSK9 are combined, so that circulating PCSK9 protein is reduced by about 90%, corresponding LDL-C level is reduced by about 55%, and the PCSK9 protein is reduced by about 90%. The effect lasts for at least 180 days. Compared with a corresponding object based on Cas9, an editor based on Cas-SF01 shows higher specificity, and off-target methylation events are fewer. The optimized LNP formulations also exhibit good safety. These findings establish a powerful and versatile platform for promoting a transient delivery-based engineered mRNA editor to achieve precise and lasting epigenetic silencing in vivo therapy.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Delivery of therapeutic proteins

The present invention relates to the treatment of diseases associated with inflammation including solid cancers. More particularly, certain methods relate to the administration (e.g., intravenously) of polyhedrin protein (PODS) crystals for the delivery of one or more therapeutic proteins. This enables targeted release of low doses of the therapeutic protein at sites of the disease.
Owner:CELL GUIDANCE SYST LTD

Use of trans-[tetrachlorobis(1h-indazole)ruthenate(III)] for the treatment of cancer

IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
Owner:BOLD THERAPEUTICS INC

Multiplexed-targeted adenovirus vectors and their use

The present application provides compositions and methods for increasing safety, selectivity, and efficacy of transduction of human cells, including human long-term repopulating and hematopoietic stem cells (LT-HSC) and human cancer cells, by adenovirus vectors through multiplexed targeting of virus attachment and internalization receptors. Multiplexing targeting Ad vector receptor specificities through the combination of i) restricting fiber-specific attachment receptors, ii) deleting the RGD amino acid motif from the penton base protein, and iii) inserting into Ad penton base protein of peptides that lack the RGD amino acid motif and enable vector interaction with integrin classes expressed on target cells, allows for the improvement of safety, selectivity, and efficacy of vector-mediated transduction of human cells in vitro and after intravenous vector administration in vivo.
Owner:ADCURE BIO LLC +1

An improved method for an ANCA-associated vasculitis mouse model induced by anti-GBM antibody

This invention discloses a method for improving a mouse model of ANCA-associated vasculitis induced by anti-GBM antibodies, relating to the field of animal model construction. The method involves subcutaneously injecting mice with 20 μg rMPO on Day 0; administering 10 μg rMPO on Day 7; subcutaneously injecting 250 μg / kg GCSF daily from Day 11 to 15; and injecting 100 μl of goat anti-GBM serum via the tail vein on Day 16 to obtain the improved mouse model. This method improves the existing anti-GBM antibody-induced ANCA-associated vasculitis mouse model by injecting GCSF. This model enhances the disease severity in ANCA-associated vasculitis mice, specifically reflecting the disease in renal pathology and proteinuria, making the differences more obvious and effectively improving the success rate of model establishment.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Subcutaneous (SC) administration of anti-C5 antibodies for treatment of complement-associated conditions

Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (SOLIRIS®) or ravulizumab (ULTOMIRIS®); particularly intravenously administered SOLIRIS® or ULTOMIRIS®.
Owner:ALEXION PHARMACEUTICALS INC

A method for constructing an animal model of glioma based on AAV-mediated immune microenvironment

The present invention discloses a method for constructing an animal model of glioma based on AAV-mediated immune microenvironment, comprising: selecting immunodeficient mice of appropriate age; injecting human CD34+ hematopoietic stem cells for immune system reconstruction; detecting human CD45+ immune cells in peripheral blood PBMC; selecting tumor tissues that highly express glioma marker genes, performing rapid qPCR or targeted RNA-seq immunohistochemistry multiple verification, and screening tumor tissues that meet the requirements; physically cutting the tumor tissue and treating it with a pretreatment solution, digesting it into a single cell suspension, and inoculating it into the mouse's skull; injecting an AAV vector carrying a specific immune regulatory gene into the mouse's tail vein to regulate the glioma immune microenvironment; when the tumor tissue is observed to grow stably and have immune cell infiltration characteristics, the construction of the glioma animal model is completed. Compared with existing models, the present invention provides a more stable, more scientific, and more human immune background glioma model, which is suitable for related immunotherapy drug screening and mechanism research.
Owner:NIKETHERAPEUTICS (HANGZHOU) CO LTD

RNA for preventing or treating tuberculosis

The present disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding variants of antigens of Mycobacterium tuberculosis ox of fragments thereof is formulated and administered in a way that the variants are produced by cells of a subject, in particular after intramuscular or intravenous administration of the RNA.
Owner:BIONTECH SE